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ABSTRACT 
Sthula Madhumeha (viz-e-viz type 2Diabetes Mellitus) is the vital problem in present era. The change in 
lifestyle and food habit is the major concern of the problem. The available drug therapy concentrating on levels 
of blood sugar rather than symptoms of patients like excessive thirst, Nocturnal enuresis, burning sensation in 
hands, feet and many more. Ayurveda emphasized more on these symptoms. These symptoms affects the 
patient’s routine life and work capacity. On behalf of these symptoms the role of Mamajjak Choorna which is 
described by Acharya Priyavrat Sharma in his book Dravya guna Vidnyan Vol. 2 page 705 found to be more 
effective in comparison to modern oral hypoglycemic and well practiced drug Metformin. Total 40 patients of 
newly diagnosed of Diabetes Mellitus were taken and divided in two groups as Trial group 20 patients on 
Mamajjak Choorna 5 gm B.I.D. given for 12 weeks. Control Group 20 patients on tab. Metformin 500 mg B.I.D. 
given for 12 weeks. 
On consumption of Mamajjak Choorna for 12 weeks it was found that there is improvement in the 
symptoms Pipasati Pravrutti (74.27%), Nakta mutrata (83.33%), Hasta-padatala daha (82.5%) Pippalika 
Sancharvaat prachti (85.71%), Prabhuta Avila mutrata (77.5%), Swedatipravritti (82.5%) so far as 
consumption of Metformin is concern, it was found as follows Pipasati Pravrutti (64.71%), Nakta mutrata 
(72.94%), Hasta-padatala daha (51.28%), Pippalika Sancharvaat prachti (50%), Prabhuta Avila mutrata 
(71.88%), Swedatipravritti (51.16%). With P<0.05 (that highly significant results in Mamajjak Choorna group). 
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INTRODUCTION
Prameha is one of the diseases which have prime 
importance, because it has been included in Mahagad[1] i.e. 
Diseases difficult to treat. Increase in frequency and 
quantity along with Turbidity of urine is the cardinal 
symptom of Madhuameha. Traditionally Madhumeha is 
rich man’s diseases. Particularly because, the person who 
is able to enjoy the pleasure of life without any physical 
work and who takes over nutritious food is more prone to 
the disease[2]. But in changing form and pattern of lifestyle 
the middle class and lower class also, suffers from this 
disease. Mainly due to stressful conditions, fast food eating, 
excessive hybrid form of diet. Charaka consider this as one 
of the varieties of Vataja Pramehas. As according to 
Sushruta, All types of Pramehas not properly treated and 
attended to at the onset, may ultimately lead to 
Madhumeha types which are incurable [3]. Whatever it may 
be the fact, Madhumeha does have the fundamental 
characters viz. Polyuria and turbidity of urine. (Prabhut 
Avila Mutrata). [4] 
 Diabetes has been recognized among a large 
number of people of various social conditions throughout 
the world especially in India. W.H.O. survey has identified 
India as a global capital of Diabetes in 2020. With abrupt 
change in the modern lifestyle, the prevalence of all type of 
Diabetes is increasing by 4 to 5% per year with an 
estimated 40-50% of individuals over the age 65 years 
having either type 2 Diabetes or impaired glucose 
tolerance. However the developing countries will bear the 
brunt of escalating epidemic in future. Modernization 
accompanying economic development in developing 
countries has been followed by a substantial increase in 
Diabetes. This global pandemic principally involves type2 
Diabetes Mellitus and it associated with several 
contributory factors including increased longevity, 
Obesity, unsatisfactory diet, sedentary lifestyle and 
increasing urbanization. 
 The Mamajjak choorna is Laghu, Ruksha Tikta ras, 
Katu vipak and Ushna virya [5], which exactly opposite to 
patho-physiological factors of Madhumeha. It was thought 
in mind to evaluate the role of Mammajak in the form of 
Choorna. As this form give more surface area for 
absorption and action starting in Amashaya which is moola 
Sthana of Kapha. 
 Taking above considerations in mind study 
entitled, “Controlled clinical evaluation of effects of 
‘Mamjjak Choorna’ in Sthula Madhumeha viz-e-viz type 2 
Diabetes mellitus”. Was planned to evaluate efficacy of 
Mamajjak choorna in the management of Sthula 
Madhumeha viz-e-viz type2 Diabetes mellitus and to 
compare its result with standard modern drug, for that 
purpose Metformin in the dose of 500mg tablet twice a day 
was given.  
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Aims and Objective 
Aim: To evaluate the efficacy of Mamajjak choorna in 
management of Sthula Madhumeha w.r.t. Type2 diabetes 
Mellitus. 
Objectives  
 Hetus [6] that are described in these texts should be 
study and observed for its presence in Pramehi 
patients, also to use this knowledge for control this 
disease. 
 Study of efficacy of “Mamajjak Choorna” in Prameha.  
Materials And Methods 
Name of Institute: Shree Saptashrungi Ayurved 
Mahavidyalaya, Nashik. 
Plan of work: The proposed study was done in two levels 
40 patients of Madhumeha divided into 2 groups 
randomly. Group one called as Trial group comprised 20 
patients, in which “Mamajjak Choorna” was given for 12 
weeks duration, while another group called as control 
group also comprises 20 patients of Madhumeha were 
given tablet of Metformin 500mg.BD was given for 12 
weeks duration. 
Type of Study – Open randomized controlled study. 
Selection of cases 
 Patients of Madhumeha were selected after clinical 
and objective examination. Follow up assessment was 
done by specially prepared case record forms of every 
patient to meet all baseline requirements. Follow up signs 
and symptoms were recorded. 
Criteria of Inclusion 
 Random selection of patients 
 Confirmed case of Diabetes mellitus (Non-insulin 
dependent)  
 Not having any Macro or Micro-vascular 
complications.  
 Both sexes. 
 Age between 25 Yr. to 65 Yr. Old. 
 The post prandial blood venous glucose level < 400 
mg/dl. 
 Fasting plasma venous glucose > 140mg/dl. 
 Body mass index of patient above 25. 
Criteria of exclusion 
 Blood glucose level (post prandial) > 450 mg/dl. 
 Age below 25 Yrs. & above 65 Yrs. will be excluded. 
 Pregnancy & lactating mothers. 
 All patient having acute complications like- 
hyperglycemic coma, ketoacidosis, infection like 
gangrene. 
 All patients having chronic complications of diabetes 
like- nephropathy, neuropathy, retinopathy etc.  
 Body Mass Index (B.M.I.) less than 25. 
Drug : The drug “Mamajjak Choorna”  
Dose: 5gm. BID  
Time of administration: Before meal morning and 
evening.  
Anupan: Luke warm water  
Duration: 12 weeks. 
Aahar: No change in regular diet. Only direct sugar or 
recipes, which contain sugar, will not be permitted. 
Follow-up: fortnightly. Laboratory investigation will be 
carried out after 4 week. 
Number of Pt: - 40 patients, each of 20 patients, in Trial 
and Control group. 
Clinical examination: A person with classical symptoms 
of Madhumeha mentioned in Ayurvedic text 
Criteria of Assessment 
A) Subjective Assessment 
 Symptoms of Madhumeha mentioned in the texts, 
and practically observed have been assessed at each follow 
up. Presence or absence of these symptoms has been 
registered. Different symptoms have been graded into 
four-grade scale (0 to 3) on the basis of severity to assess 
the changes in clinical symptoms of Madhumeha. Study of 
changes in the gradation of each symptom has been done 
in each follow up.  
B) Objective Assessment 
 All patients were randomly selected for the study 
irrespective of Sex, Marital status, Educational status and 
Economical status. They were randomly classified as Trial 
group and Control group. All the patients selected for the 
therapy have been assessed on clinical, physical and 
hematological parameters. 
1. Blood sugar fasting and post prandial sugar will be 
estimated every 4 weeks. 
2. Glycosylated hemoglobin (HbA1C) will be estimated at 
the entry point and at the end of the study to assess 
the level of average glycaemic control during the trial. 
3. Lipid profile will be estimated at the starting and end 
point of study to assess the status of dys-lipidemia 
commonly found in Diabetes. 
4. Effect of therapy has been assessed to observe any 
change in clinical symptoms by every week. 
5. Total effect of therapy has been assessed on patients 
in terms cured, Improved, Markedly improved and 
Unchanged. These terms have been explained here in, 
later on. 
Gradation of Symptoms: [7] 
1. Daurbalya 
Grade 0: No weakness in any sort of work 
Grade 1: Weakness in routine work but able to cope up 
Grade 2: Weakness enough to hamper routine work 
Grade 3: Weakness in slight work or at rest requiring bed rest. 
2. Kshudhavrudhhi 
Grade 0: Two meals a day 
Grade 1: Three meals a day 
Grade 2: Four meals a day 
Grade 3: Four meals a day but still feels hungry. 
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3.Pipasatipravrutti 
Grade 0: Need normal amount of water to satisfy quench 
Grade 1: Need water twice than normal for himself for quench 
Grade 2: Need water thrice than normal for himself for quench 
Grade 3: Not satisfying after drinking abundant of water  
4. Prabhuta Avila Mutrata 
Grade 0: Urine output between 1500 – 2000 ml per 24 hour with no turbidity of urine  
Grade 1: Urine output between 2000 – 2500 ml per 24 hour with less turbidity of urine 
Grade 2: Urine output between 2500 – 3000 ml per 24 hour with moderate turbidity of 
urine 10 – 12 glasses of water a day 
Grade 3: Urine output more than 3000 ml per 24 hour with severe turbidity of urine 
5. Nakta mutrata 
Grade 0: No nocturnal micturation.  
Grade 1: 1 – 2 times passing of urine at night 
Grade 2: 2 – 4 times passing of urine at night. 
Grade 3: more than 4 times passing of urine at night 
6. Pindikodweshtana 
Grade 0: No cramps 
Grade 1: Cramps after 1 hour of walk  
Grade 2: Cramps after 1/2 hour of walk  
Grade 3: Cramps after 10 minutes of walk 
7. Swedatipravrutti 
Grade 0: No Swedatipravritti 
Grade 1: Swedatipravritti on more exertion 
Grade 2: Swedatipravritti on little exertion 
Grade 3: Swedatipravritti at rest 
8. Hasta-paad tala Daha 
Grade 0: No burning sensations  
Grade 1: Burning sensation that is not continuous does not disturb routine activity 
Grade 2: Continuous burning sensation does not disturb routine activity 
Grade 3: Severe continuous burning sensation disturbs routine activity 
9. Pipilika Sancharvaat Prachiti 
Grade 0: No tingling sensations 
Grade 1: Tingling sensation that is not continuous does not disturb routine activity 
Grade 2: Continuous tingling sensation does not disturb routine activity 
Grade 3: Severe continuous tingling sensation disturbs routine activity  
Analysis  
 The fortnightly follow-up of patients has been done as regards the symptomatic improvement and blood sugar 
level has been monitored every 4 weeks interval. Statistical analysis has been done. 
Observation and Results 
Table 1: Showing Effect On Symptoms Score Of 40 Patients Of Diabetes Mellitus (BT=Before Treatment ; AT= After 
Treatment ; Diff= Difference) 
Sr. No Symptom 
Trial Group Control Group 
BT AT Diff. 
Percent-age 
of relief 
BT AT Diff. 
Percentag
e of relief 
1 Daurbalya 40 11 29 72.5% 36 8 26 77.78% 
2 Pipasati Pravrutti 35 9 26 74.27% 34 12 22 64.71% 
3 Nakta mutrata 36 6 30 83.33% 37 10 27 72.94% 
4 Hasta-padatala daha 40 7 33 82.5% 39 19 20 51.28% 
5 Pippalika Sancharvaat prachti 40 9 31 77.5% 34 17 17 50% 
6 Prabhuta Avila mutrata 40 7 33 82.5% 32 9 23 71.88% 
7 Pindikodweshtan 35 6 29 82.86% 32 14 18 56.25% 
8 Swedatipravritti 42 6 36 85.71% 43 21 22 51.16% 
9 Kshudha vruddhi 33 4 29 87.88% 34 14 20 58.82% 
 Average Score 37.6 72.22 3.66 81.51% 35.66 13.77 21.66 60.74% 
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Table 2: Showing Effect On Symptoms Of 40 Patients Of Diabetes Mellitus Of Trial Group By Wilcoxson-Matched-
Pairs-Signed-Ranks Test 
No. Symptom Mean SD SEd 
Sum of all 
Signed Ranks 
No. Of 
Pairs 
Z P 
1 Daurbalya  
BT  
AT  
Diff. 
  
2  
0.55 
1.45 
  
0.7255 
0.5104 
0.6048 
  
0.1622 
0.1141 
0.1325 
210 20 3.9201 <0.001 
2 Pipasati Pravrutti 
BT  
AT  
Diff. 
  
1.75 
0.45  
1.3 
  
 0.6387 
0.5104 
0.6048 
  
0.1428 
0.1141 
0.1933 
163 16 4.2104 <0.001 
3 Nakta mutrata  
BT  
AT  
Diff. 
 
1.8  
0.3  
1.5 
 
0.6958 
0.4702 
0.6882 
  
0.1556 
0.1051 
0.1539 
190 19 3.8229 <0.001 
4 Hasta-padatala daha  
BT  
AT  
Diff. 
  
2  
0.35 
1.65 
  
0.7255 
0.4893 
0.4893 
  
0.1622 
0.1094 
0.1094 
210 20 3.9201 <0.001 
5 Pippalik Sanchar prachiti  
BT  
AT  
Diff. 
  
2  
0.45 
1.55 
  
0.7255 
0.51042 
0.6048 
  
0.1622 
0.1141 
0.1352 
210 
 
20 
 
3.9201 
 
<0.001 
6 Prabhuta Avila mutrata  
BT  
AT  
Diff. 
  
2  
0.35 
1.65 
  
0.7947 
0.4893 
0.5871 
  
0.1771 
0.1094 
0.1313 
210 20 3.9201 <0.001 
7 Pindikodweshtan  
BT  
AT  
Diff. 
 
1.75  
0.3  
1.45 
  
0.7163 
0.4701 
0.7591 
  
0.1601 
0.1053 
0.1697 
171 18 3.7238 <0.001 
8 Swedatipravritti  
BT  
AT  
Diff 
 
2.1  
0.3  
1.8 
 
0.7881 
0.4702 
0.8944 
 
0.1762 
0.1501 
0.2 
190 19 3.8229 <0.001 
9 Kshudha vruddhi  
BT  
AT  
Diff. 
 
1.65  
0.2  
1.45 
 
0.5971 
0.4104 
0.5104 
 
0.1313 
0.0917 
0.1141 
 210  20  3.9201 
 
<0.001 
(BT=Before Treatment ; AT= After Treatment ; Diff= Difference) 
Table 3: Showing Effect on Symptoms Of 40 Patients Of Diabetes Mellitus Of Control Group By Wicoxson-Matched-
Pairs-Signed-Ranks Test 
No. Symptom Mean SD SEd 
Sum of all 
Signed Ranks 
No. Of 
Pairs 
Z P 
1 Daurbalya  
BT  
AT  
Diff 
 
1.8  
0.4  
1.4 
  
0.6959 
0.5062 
0.5982 
  
0.1556 
0.1124 
0.1337 
210 20 3.9201 <0.001 
2 Pipasati Pravrutti  
BT  
AT  
Diff. 
 
1.7  
0.6  
1.1 
  
0.6569 
0.5026 
0.4472 
 
0.1469 
0.1123 
0.1 
190 19 3.8229 <0.001 
3 Nakta mutrata  
BT  
AT  
Diff. 
 
1.85 
0.5 
1.35 
 
0.6708 
0.5129 
0.9880 
  
0.15 
0.1147 
0.2209 
210 20 3.9201 <0.001 
4 Hasta-padatala daha  
BT  
AT  
 
1.95 
0.9 
 
0.6863 
0.6048 
  
0.1534 
0.1352 
153 17 3.6213 <0.001 
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Diff. 5 1 0.5619 0.1256 
5 Pippilika Sancharvaat 
prachiti  
BT  
AT  
Diff. 
  
1.7 
0.85 
0.85 
  
0.8645 
0.6708 
0.5871 
  
0.1933 
0.15 
0.1312 
 
171 
 
18 
 
3.7238 
 
<0.001 
6 Prabhuta Avila mutrata 
BT  
AT  
Diff. 
  
1.6 
0.45 
1.15 
  
0.7539 
0.6048 
0.8127 
  
0.1685 
0.1352 
0.1337 
 
171 
 
18 
 
3.7238 
 
<0.001 
7 Pindikodweshtan  
BT  
AT  
Diff. 
  
1.6 0.7 
0.9 
  
0.5982 
0.5712 
0.5525 
  
0.1337 
0.1277 
0.1235 
 
136 
 
16 
 
3.5160 
 
<0.001 
8 Swedatipravritti  
BT  
AT  
Diff. 
  
2.15 
1.05 
1.1 
  
0.7451 
0.7591 
0.5525 
  
0.1666 
01697 
0.1235 
171 18 3.7238 <0.001 
9 Kshudha vruddhi  
BT  
AT  
Diff. 
  
1.7  
0.7  
1 
  
0.5712 
0.5327 
0.5619 
  
0.1277 
0.1638 
0.1256 
190 19 3.8229 <0.001 
(BT=Before Treatment; AT= After Treatment ; Diff= Difference) 
Table 4: Showing Comparison between Two Groups with Respect to Symptoms Score By Mann-Whitney Test 
Sr. No. Symptoms R1 Mean U SD Mean + 1.96 SD Z P 
1 Daurbalya 419.5 200 190.5 38.97 123.63 -276.38 0.2309 >0.05 
2 Pipasati Pravrutti 351 152 89 30.2 92.8-211.19 2.069 <0.05 
3 Nakta mutrata 307.2 142.5 167.8 28.83 85.99-119 0.8602 >0.05 
4 Hasta-padatala daha 460.5 170 89.5 32.81 105,69-234.3 2.42 <0.05 
5 Pippalika Sancharvaat prachti 416 150 94 30 91.2-208.8 1.85 <0.05 
6 Prabhuta Avila mutrata 385.84 160 143.5 31.41 98.43-221.56 1.068 >0.05 
7 Pindikodweshtan 320.5 144 138.25 28.98 87.199-200.8 0.1725 >0.05 
8 Swedatipravritti 441 171 91 32.9 106.51-235.48 2.214 <0.05 
9 Kshudha vruddhi 426.5 170 123.5 32.81 105.69-234.31 1.4 <0.05 
Table 5: Showing Variance Ratio Test Before treatment on Hematological Parameter 
Sr. No. 
Hematological 
parameter 
Before Treatment SD 
F ratio P Value 
Trial Group SD1 Control Group SD2 
1 BSL(F) 50.5109 52.5439 1.0821 > 0.05 
2 BSL(PP) 57.2458 67.0478 1.3717 > 0.05 
3 Total Cholesterol 37.0352 42.4600 1.3144 > 0.05 
4 USL 0.8825 0.8207 1.1562 > 0.05 
Variance Ratio Test Before Treatment 
 Variance ratio test was evaluated in this study to see the difference between mean values of hematological 
parameters. 
 Variance ratio for Blood sugar level fasting, Post prandial, total Cholesterol and Urine sugar levels presented in the 
table showed that there was no significant difference between two groups with respect to these Hematological 
parameters. 
 Therefore further statistical evaluation was done to see the difference between two groups with respect to these 
character only by unpaired ‘t’ test. 
Table 6: Showing Comparison between two Groups by Unpaired ‘t’ Test on Hematological Parameters 
Sr.No 
Hematological 
parameter 
Mean of Difference +SD 
SEd 
t 
 
P 
 Trial Group Control Group 
1 BSL(F) 16.2 + 34.75 61.65 + 4.40 10.9335 4.1569 <0.001 
2 BSL(PP) 27.1 + 7.78 76.75 + 53.95 17.6776 2.8086 < 0.05 
3 USL 0.75 + 1.0195 1 + 0.6488 0.2702 0.9251 > 0.05 
4 Total Cholesterol 18.35 + 27.681 32.85 + 32.4885 9.5439 1.5193 > 0.05 
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Table 7: Showing total effect of therapy in 40 Patients of Madhumeha 
Sr. No. 
Total effect of 
therapy 
Trial Group Control Group Total 
No of Pts % No of Pts % No of Pts Percentage 
1 Cured 0 0% 0 0% 0 0% 
2 Markedly improved 12 60% 13 65% 25 62.5% 
3 Improved 8 40% 7 35% 15 37.5% 
4 Unchanged 0 0% 0 0% 0 0% 
 5 LAMA 0 0% 0 0% 0 0% 
Total Effect of Therapy 
In case of trial group 12 patients (60%) were markedly improved and 8 patients (40%) were improved. In case of control 
group 13 patients (65%) were markedly improved and 7 patients (35%) were improved.  
Table 8: Showing Comparison between two Groups by Chi-Square test 
Sr. No Group Improved Marked Improved Total Chi-Square value 
1 Trial Group 
(O)=8 (O)=12 
20 
0.1067 
P > 0.05 
(E)=7.5 (E)=12.5 
2 Control Group 
(O)=7 (O)=13 
20 
(E)=7.5 (E)=12.5 
 Total   40  
CONCLUSION 
It is observed that there was significant 
improvement in symptoms in both the groups. Comparison 
between two groups with respect to symptom score was 
statistically evaluated by Mann - Whitney test. There was 
significant difference found between Trial and control 
group in Hasta Paadatala Daha, Pipilika Sanchaarvat 
Prachiti, Swedatipravrutti, Kshudha vrudhhi symptoms. 
That Difference is significant at P<0.05 level of confidence. 
As the means of difference of these symptoms in the trial 
group was more than control group, it can be concluded 
that the drug under trial (Mamajjak choorna) acts better 
with respect to these symptoms than control. 
Blood sugar level (fasting), blood sugar level (Post-
prandial), total cholesterol and urine sugar level were 
significantly decreased in both trial and control groups. 
Comparison between two group was done by unpaired ‘t’ 
test. There was highly significant in BSL (F) and BSL (PP). 
Hence it can be concluded from the mean that drug in the 
control group act significantly on these hematological 
parameters than the trial medicine. 
 In case of urine sugar level and total cholesterol 
the unpaired ‘t’ comes out to be insignificant.  
 In case of trial group out of 20 patients 12 patients 
were markedly improved and 8 patients were improved. 
While in case of control group, out of 20 patients 13 were 
markedly improved and 7 were improved. Comparison 
between two groups was done by Chi-square test. It was 
found that there was no significant difference between the 
two groups. 
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